title: Advancing drug innovation for neglected diseases-criteria for lead progression.
abstract: The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Access to technologies, resources, and strong management as well as clear compound progression criteria are factors in the successful implementation of any collaborative drug discovery effort. We discuss how some of these factors have impacted drug discovery for tropical diseases within the past four decades, and highlight new opportunities and challenges through the virtual North-South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation. A set of criteria designed to facilitate compound progression from screening hits to drug candidate selection is presented to guide ongoing efforts.
authors.affiliation: Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland.
authors.forename: Solomon
authors.initials: S
authors.lastname: Nwaka
authors.forename: Bernadette
authors.initials: B
authors.lastname: Ramirez
authors.forename: Reto
authors.initials: R
authors.lastname: Brun
authors.forename: Louis
authors.initials: L
authors.lastname: Maes
authors.forename: Frank
authors.initials: F
authors.lastname: Douglas
authors.forename: Robert
authors.initials: R
authors.lastname: Ridley
references.citation: Nat Rev Drug Discov. 2004 Aug;3(8):673-83
references.pmid: 15286734
references.citation: Science. 2005 Jul 15;309(5733):436-42
references.pmid: 16020728
references.citation: Nat Rev Drug Discov. 2007 Jan;6(1):29-40
references.pmid: 17159923
references.citation: Lancet. 2002 Jun 22;359(9324):2188-94
references.pmid: 12090998
references.citation: Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S4-8
references.pmid: 16904717
references.citation: Nature. 2005 Mar 10;434(7030):214-7
references.pmid: 15759000
references.citation: Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15
references.pmid: 15331814
references.citation: Nat Rev Drug Discov. 2002 Jan;1(1):45-54
references.pmid: 12119609
references.citation: Expert Opin Drug Discov. 2007 Oct;2(s1):S3-7
references.pmid: 23489030
references.citation: Nat Rev Drug Discov. 2008 Nov;7(11):900-7
references.pmid: 18927591
references.citation: Nat Rev Drug Discov. 2003 May;2(5):369-78
references.pmid: 12750740
references.citation: PLoS Med. 2007 Nov 6;4(11):e293
references.pmid: 17988169
references.citation: N Engl J Med. 2008 Dec 11;359(24):2619-20
references.pmid: 19064625
references.citation: Drug Discov Today. 2005 Jan 1;10(1):17-22
references.pmid: 15676295
references.citation: Science. 2005 Jul 15;309(5733):401-4
references.pmid: 16020723
references.citation: PLoS Med. 2005 Sep;2(9):e302
references.pmid: 16138789
references.citation: Science. 2005 Jul 15;309(5733):409-15
references.pmid: 16020725
references.citation: Nat Rev Drug Discov. 2003 Nov;2(11):919-28
references.pmid: 14668812
references.citation: Adv Parasitol. 2006;61:349-94
references.pmid: 16735169
references.citation: Science. 2007 Sep 21;317(5845):1756-60
references.pmid: 17885136
references.citation: Parasitology. 2007;134(Pt 8):1073-6
references.pmid: 17608966
references.citation: J Biol Chem. 2005 Jun 10;280(23):21847-53
references.pmid: 15795226
references.citation: Postgrad Med J. 2006 Dec;82(974):788-98
references.pmid: 17148699
references.citation: Expert Opin Drug Discov. 2007 Oct;2(s1):S53-61
references.pmid: 23489033
references.citation: Nat Rev Drug Discov. 2006 Nov;5(11):941-55
references.pmid: 17080030
references.citation: Nat Rev Drug Discov. 2005 Sep;4(9):727-40
references.pmid: 16138106
references.citation: Nature. 2002 Oct 3;419(6906):498-511
references.pmid: 12368864
references.citation: Expert Opin Drug Discov. 2007 Oct;2(s1):S63-73
references.pmid: 23489034
references.citation: Expert Opin Drug Discov. 2007 Oct;2(s1):S41-52
references.pmid: 23489032
references.citation: Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):19-51
references.pmid: 18221162
references.citation: Exp Parasitol. 2007 Nov;117(3):225-8
references.pmid: 17643433
references.citation: Expert Opin Drug Discov. 2007 Oct;2(s1):S99-S103
references.pmid: 23489039
references.citation: J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49
references.pmid: 11274893
references.citation: Science. 2005 Jul 15;309(5733):416-22
references.pmid: 16020726
references.citation: Health Aff (Millwood). 2006 Mar-Apr;25(2):420-8
references.pmid: 16522582
references.citation: Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S21-5
references.pmid: 16730039
references.citation: J Health Econ. 2003 Mar;22(2):151-85
references.pmid: 12606142
references.citation: Nat Rev Drug Discov. 2002 Nov;1(11):882-94
references.pmid: 12415248
references.citation: Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S20-9
references.pmid: 16085175
references.citation: Bioorg Med Chem Lett. 2007 Mar 1;17(5):1422-7
references.pmid: 17194585
references.citation: Nature. 2004 Aug 19;430(7002):900-4
references.pmid: 15318224
references.citation: PLoS Med. 2005 Aug;2(8):e210
references.pmid: 16120007
references.citation: Nature. 2007 Sep 13;449(7159):166-9
references.pmid: 17851512
references.citation: Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S9-14
references.pmid: 16087204
references.citation: J Clin Invest. 2008 Apr;118(4):1266-76
references.pmid: 18382739
references.citation: J Enzyme Inhib Med Chem. 2008 Oct;23(5):708-18
references.pmid: 18671165
references.citation: Ernst Schering Res Found Workshop. 2003;(42):11-7
references.pmid: 12664532